480 related articles for article (PubMed ID: 36796982)
21. Lower cost strategies for triage of human papillomavirus DNA-positive women.
Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
[TBL] [Abstract][Full Text] [Related]
22. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
23. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
[TBL] [Abstract][Full Text] [Related]
24. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
25. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
27. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of combined molecular and morphology-based triage for HPV-positive women in routine cervical cancer screening services from Colombia.
Murillo R; Gamboa O; Hernández G; González M; Olejua P; Molano M; Wiesner C
Prev Med; 2021 Dec; 153():106801. PubMed ID: 34508733
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
30. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
[TBL] [Abstract][Full Text] [Related]
31. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
32. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
[TBL] [Abstract][Full Text] [Related]
33. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
34. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
[TBL] [Abstract][Full Text] [Related]
36. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
37. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
[TBL] [Abstract][Full Text] [Related]
38. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
[TBL] [Abstract][Full Text] [Related]
39. The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer.
Jeronimo J; Bansil P; Valdez M; Kang LN; Zhao FH; Qiao YL; Chen W; Zhang X; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
J Low Genit Tract Dis; 2015 Jul; 19(3):220-3. PubMed ID: 25279978
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]